PE Tech Report


Like this article?

Sign up to our free newsletter

Keensight Capital to reinvest in Menix

Keensight Capital is to reinvest in Menix, a French leader in hip prosthesis and a major player in dental implants solutions; alongside the Company’s management team, led by Patrick Rondot, Jean-Luc Aurelle and Christophe Marrone, Five Arrows Principal Investments and Turenne Capital.

Based in Lyon, Menix is a specialist in dual mobility hip prosthesis, in France and internationally. The concept of dual mobility cup, which was invented and developed by the company, reduces significantly the dislocation risk linked to hip replacement surgery. Menix has also developed a reputation as a leader in dental implants and Cranio-Maxillo-Facial surgery in France.
Experiencing a 15 per cent compound annual revenue growth over the past years, Menix plans to continue its development, notably by extending its product offering with the launch of a new range of knee prostheses, by accelerating international sales growth, as well as through new targeted acquisitions in France and in Europe.
Patrick Rondot, CEO of Menix, says: “We are delighted to be joining forces with Five Arrows Principal Investments, which has demonstrated a deep understanding of our business sector and our key differentiating assets. We want to thank Keensight Capital for their renewed trust in our onward journey. Thanks to its thorough knowledge and expertise in orthopedics, Keensight has played a decisive role as supportive shareholder with strong value-added impact.”
Pierre Rémy, Managing Partner at Keensight Capital, adds: “We are pleased to see Menix embarking on a new and exciting phase of its development. During our 3-year tenure as shareholder, the Company has strengthened its leadership position in orthopedics and has substantially grown its presence in dental implants solutions; a string of successes which have been achieved by a high-caliber management team. By reinvesting in Menix, we remain committed to support Patrick Rondot and his team in achieving ambitious growth plans, both organically notably with the launch of a new complete set of knee implants, and through external growth.”

Like this article? Sign up to our free newsletter